Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.